when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

1,499 stories

May 28, 26GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’biopharma dive

May 28, 26AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchaseendpoints

May 27, 26AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Waveendpoints

May 22, 26FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infectionfda press

May 19, 26A migraine drugmaker heads to the public markets through reverse mergerbiopharma dive

May 19, 26Relay drug shows early promise against rare blood vessel diseasesbiopharma dive

May 19, 26Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies studyendpoints

May 18, 26Merck ADC, licensed from China, hits mark in first big global trialbiopharma dive

May 18, 26Regeneron reaches $125M Parabilis deal for hard-to-catch drug targetsendpoints

May 18, 26Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drugbiopharma dive

May 18, 26Merck's ADC sac-TMT gets its first global Phase 3 win ahead of scheduleendpoints

May 18, 26Regeneron immunotherapy combo comes up short in melanoma trialbiopharma dive

May 18, 26Texas is opening up a detransition clinicstat

May 18, 26Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3endpoints

May 17, 26In Ebola outbreak, a number of Americans in the Congo believed to have had exposure to suspected casesstat

May 17, 26When should you get a mammogram? Conflicting advice makes it hard to knowstat

May 16, 26Dr Meeks on a Real-World Study of BCG Retreatment After BCG Failure in NMIBConclive

May 16, 26Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Canceronclive

May 16, 26Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Yearsonclive

May 16, 26Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBConclive

May 16, 26Opinion: Marty Makary misunderstood something fundamental about the FDAstat

May 15, 26Dr Croll on Radiographic Size Change vs irRVT After Neoadjuvant Therapy in RCConclive

May 15, 26FDA Approves T-DXd for Early-Stage HER2+ Breast Canceronclive

May 15, 26Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Canceronclive

May 15, 26STAT+: FDA leadership shakeup widens following Makary’s departurestat

May 15, 26Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBConclive

May 15, 26Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trialonclive

May 15, 26Darolutamide Plus ADT Yields Significant OS Benefit in mHSPConclive

May 15, 26OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?onclive

May 15, 26Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBConclive

← prevpage 41 of 50next →